跳至主要内容
临床试验/NCT02713542
NCT02713542已完成不适用

Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)

Arthrex, Inc.8 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2016年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Arthrex, Inc.
入组人数
90
试验地点
8
主要终点
Pain Scores Measured by Western Ontario and McMaster Universities Index (WOMAC) Survey

研究概览

简要总结

This study is primarily investigating the effectiveness of Autologous Conditioned Plasma (ACP) Intra-articular (IA) in patients with Osteoarthritis (OA) in the knee.

详细描述

This study is a prospective, multi center randomized double blind, two arm study.

90 subjects will be randomized to receive injections of either Autologous Conditioned Plasma Intra-articular or the control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject is 18 to 70 years of age.
  • The subject presents with complaints of continued pain of primary knee for at least 6 weeks.
  • The subject has documented radiographs evidence of Osteoarthritis (OA) in the tibio-femoral or patella-femoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 24 weeks of screening.
  • The subject has a WOMAC pain score of at least 8 out of 20 and at least moderate pain (a score of 2) for at least 2 questions on activities

排除标准

  • Grade I and IV on the knee Kellgren-Lawrence grading scale
  • Subject has clinically 3+ effusion of the target knee (stroke test grading system).
  • Subject has significant (> 10⁰) valgus or varus deformities as evidenced by standard of care X-ray.
  • Subject has had systemic or IA injection of corticosteroids in any joint within three months prior to screening.
  • Viscosupplementation in any joint in the past six months.
  • Subject has an increased risk for post- procedure bleeding (e.g., bleeding disorder or taking anticoagulants except low-dose aspirin).
  • Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
  • Subject has inflammatory disease of either knee other than OA.
  • Subject with underlying medical conditions that could interfere with the evaluation of the outcome.
  • Subject with positive pregnancy test, or breast feeding.
  • Subject with plans to participate in other clinical trial involving medical or surgical intervention in the next 12 months.
  • Subject with any condition (including cognitive impairment) that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • Subject has rheumatoid arthritis or gout
  • Subject has a history of or a current infection at the affected joint.
  • Subject with plans to undergo any elective orthopedic surgery in the next 12 months.
  • Subject requires pain management therapy (with the exception of acetaminophen) not related to the target knee.

研究组 & 干预措施

Normal Saline (NS)

Placebo Comparator

3 NS Intra-articular (IA) injections at 1 week intervals

干预措施: Placebo (Other)

Autologous Conditioned Plasma (ACP)

Experimental

3 Intra-articular (IA) injections at 1 week intervals

干预措施: ACP (Device)

结局指标

主要结局

Pain Scores Measured by Western Ontario and McMaster Universities Index (WOMAC) Survey

时间窗: 6 month visit

The WOMAC Pain score will be used to measure outcome, the score ranges from 0 to 20. The higher the score indicates greater pain.

次要结局

未报告次要终点

研究者

发起方
Arthrex, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Autologous Conditioned Plasma (ACP) Intra-articular... | 临床试验